TheStreet

Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Already have an account? Login here
TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTCRYPTOMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTERTECHNOLOGY
Search

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

SUBSCRIBE NOW

LATEST NEWS

AstraZeneca Heart Drug Trial No Longer Subject of a Federal Probe
Play
INVESTING

Amarin Shares Crushed After Judge Rules Heart Drug Patents Invalid: Report

  • By Tom Bemis
  • Mar 30, 2020 6:37 PM EDT
PRESS RELEASES

Grifols 2020 Annual Report On Form 20-F Filed With The SEC On April 9, 2021

  • By PR Newswire
  • Apr 9, 2021 10:30 AM EDT
PRESS RELEASES

Grifols Announces Topline Data From NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Hyperimmune Globulins As A Treatment For Hospitalized Patients With COVID-19

  • By PR Newswire
  • Apr 2, 2021 11:18 AM EDT
PRESS RELEASES

Grifols Reinforces Its Innovation Strategy After Completing The Acquisition Of GigaGen To Boost A Novel Method To Generate A Wide Range Of Immunoglobulins

  • By PR Newswire
  • Mar 9, 2021 3:15 AM EST
PRESS RELEASES

Grifols PharmacyKeeper Ranked No. 1 As 'Best In KLAS' For Fifth Consecutive Year

  • By PR Newswire
  • Feb 23, 2021 9:00 AM EST
PRESS RELEASES

Grifols Begins Clinical Trial Of A New Treatment That Would Provide Immediate Immunity Against COVID-19

  • By PR Newswire
  • Jan 18, 2021 6:00 AM EST
PRESS RELEASES

The Dow Jones Sustainability Index Recognizes Grifols As One Of The World's Most Sustainable Companies

  • By PR Newswire
  • Nov 16, 2020 9:14 AM EST
PRESS RELEASES

Grifols Partners With TRC Healthcare To Streamline Intravenous Compounding Education

  • By PR Newswire
  • Nov 12, 2020 9:00 AM EST
PRESS RELEASES

Grifols' Anti-SARS-CoV-2 Hyperimmune Globulin Begins Clinical Trial In Patients With COVID-19

  • By PR Newswire
  • Oct 9, 2020 6:23 AM EDT
PRESS RELEASES

Grifols Closes The Acquisition Of Green Cross Fractionation Plant In Canada And 11 Plasma Centers In The U.S.

  • By PR Newswire
  • Oct 1, 2020 12:13 PM EDT
PRESS RELEASES

Grifols To Acquire Alkahest To Enhance Discovery Research And Development To Identify Innovative Therapies For Age-related Diseases Based Upon An Understanding Of The Human Plasma Proteome

  • By PR Newswire
  • Sep 7, 2020 2:50 AM EDT
PRESS RELEASES

ICU Medical Broadens Its Non-PVC/Non-DEHP IV Solutions Portfolio By Entering Long-Term U.S. Distribution Agreement With Grifols For Certain Core IV Solution Products

  • By PR Newswire
  • Aug 10, 2020 4:00 PM EDT
PRESS RELEASES

Grifols Delivers First Manufactured Batches Of Its Anti-SARS-CoV-2 Hyperimmune Globulin For Clinical Trials

  • By PR Newswire
  • Jul 28, 2020 10:41 AM EDT
PRESS RELEASES

Results Of Grifols' AMBAR Clinical Trial Published In Alzheimer's & Dementia: The Journal Of The Alzheimer's Association

  • By PR Newswire
  • Jul 27, 2020 1:18 PM EDT
PRESS RELEASES

Grifols To Acquire Green Cross Plasma Fractionation Facility In Montreal And A Plasma Collection Organization In The U.S. For US$460 Million

  • By PR Newswire
  • Jul 20, 2020 2:39 AM EDT
PRESS RELEASES

Rigel Announces Availability Of TAVLESSE® (Fostamatinib Disodium Hexahydrate) In Europe

  • By PR Newswire
  • Jul 9, 2020 8:19 AM EDT
PRESS RELEASES

Grifols Starts Production Of Its Hyperimmune Immunoglobulin As A Potential Passive Immune Therapy Against COVID-19

  • By PR Newswire
  • Jun 11, 2020 4:03 AM EDT
PRESS RELEASES

Racing Against Time, Medical Researchers, Life Science Companies And COVID-19 Survivors Launch National Campaign To Drive Blood Plasma Donation

  • By PR Newswire
  • May 26, 2020 9:00 AM EDT
PRESS RELEASES

Grifols Procleix Panther System With Automation Ready Technology (ART) Receives FDA Approval

  • By PR Newswire
  • May 7, 2020 9:00 AM EDT
PRESS RELEASES

Grifols Launches New 3-mL (900-IU) Vial For High-potency HyperRAB® (rabies Immune Globulin [human])

  • By PR Newswire
  • Apr 28, 2020 9:00 AM EDT
PRESS RELEASES

Grifols 2019 Annual Report On Form 20-F Filed With The SEC On April 6, 2020

  • By PR Newswire
  • Apr 6, 2020 9:30 AM EDT
AstraZeneca Heart Drug Trial No Longer Subject of a Federal Probe
INVESTING

Amarin Shares Crushed After Judge Rules Heart Drug Patents Invalid: Report

  • By Tom Bemis
  • Mar 30, 2020 6:37 PM EDT
PRESS RELEASES

Grifols PharmacyKeeper Ranked No. 1 In KLAS Rating, Extends Category Leadership

  • By PR Newswire
  • Feb 13, 2020 9:00 AM EST
Loxo Drug Notches Strikingly High Response Rates in Genetically Defined Tumors
MERGERS AND ACQUISITIONS

Hologic agrees to sell blood screening business to Grifols for $1.7B

  • By Bill Meagher
  • Dec 14, 2016 7:14 PM EST
Valeant Stock Jumps After John Paulson Named to Board
OPINION

5 big dividend stocks John Paulson loves

  • By Emily Stewart
  • Sep 8, 2016 7:39 AM EDT
TheStreet
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
© 2021 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.